Shafaati, Maryam, Jamalidoust, Marzieh, ziyaeyan, Mazyar, Kargar, Mohammad, Arefian, Ehsan (2018). Liver micro-RNAs and their role in different HCV genotype infections. , 20(4), 1-19.
Maryam Shafaati; Marzieh Jamalidoust; Mazyar ziyaeyan; Mohammad Kargar; Ehsan Arefian. "Liver micro-RNAs and their role in different HCV genotype infections". , 20, 4, 2018, 1-19.
Shafaati, Maryam, Jamalidoust, Marzieh, ziyaeyan, Mazyar, Kargar, Mohammad, Arefian, Ehsan (2018). 'Liver micro-RNAs and their role in different HCV genotype infections', , 20(4), pp. 1-19.
Shafaati, Maryam, Jamalidoust, Marzieh, ziyaeyan, Mazyar, Kargar, Mohammad, Arefian, Ehsan Liver micro-RNAs and their role in different HCV genotype infections. , 2018; 20(4): 1-19.

Liver micro-RNAs and their role in different HCV genotype infections

Pathobiology Reserach
Article 1, Volume 20, Issue 4, 2018, Pages 1-19    PDF (1.56 M)
Authors
Maryam Shafaati1; Marzieh Jamalidoust* 2; Mazyar ziyaeyan2; Mohammad Kargar3; Ehsan Arefian4
1Young Researchers Club, Department of Microbiology Management, College of Science Jahrom branch, Islamic Azad University, Jahrom, Fars, Iran
2Department of virology, Prof. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Microbiology, Faculty of Sciences, Islamic Azad University, Jahrom Branch, Iran.
4Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran
Abstract
Hepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The combination of ribavirin and peg-interferon, as standard treatment for HCV infection, seems very promising. Many studies have revealed that despite following standard HCV treatment, a high proportion of HCV genotypes 1 and 4 poorly attain (42% to 46%) the SVR condition, whereas it is somehow easier for HCV genotypes 2 and 3 (76%-82%). Overall, genotypes 1 and 4 antiviral therapies must be continued up to one year to achieve SVR, whereas in individuals infected with genotypes 2 and 3 must continue therapy for six months. Since 2011, direct-acting antiviral agents (DAA) have been introduced that target the HCV-encoded proteins which are vital for replication of the virus. The first generation of DAA, telaprevir, in combination with peg-interferon and ribavirin, more efficiently inhibits replication of genotype 1. Although the level of DAA SVR rate is high, the new treatment has some undesirable adverse effects. Micro-RNAs (miRNAs), as the new HCV drug approach, open a new insight into the treatment of non-responder HCV patients. Altered expression of miRNAs is involved in the aspects of HCV infection and HCC. In the current review, we attempt to better understand the HCV life cycle, liver miRNAs, and their role in this viral infection.
Keywords
Hepatitis C virus; liver miRNA; New drugs; HCV genotypes
References
Statistics
Article View: 157
PDF Download: 97
Statistics
Number of Journals45
Number of Issues2,196
Number of Articles24,877
Article View28,768,001
PDF Download18,603,202